PT  - JOURNAL ARTICLE
AU  - Cherednik, Ivan
TI  - A Surprising formula for the spread of Covid-19 Under Aggressive Management
AID  - 10.1101/2020.04.29.20084483
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.29.20084483
4099  - http://medrxiv.org/content/early/2020/10/07/2020.04.29.20084483.short
4100  - http://medrxiv.org/content/early/2020/10/07/2020.04.29.20084483.full
AB  - We propose an algebraic-type formula that describes with high accuracy the total number of detected infections for the Covid-19 pandemic in many countries. Our 2-phase formula can be used as a powerful forecasting tool. It is based on the author’s new theory of momentum management of epidemics; Bessel functions are employed. Its 3 parameters are the initial transmission rate, reflecting the viral fitness and “normal” frequency of contacts in the infected areas, and the intensity of prevention measures at phases 1, 2. Austria, Brazil, Germany, Japan, India, Israel, Italy, the Netherlands, Sweden, Switzerland, UK, and the USA are considered, including the second wave in the latter. The forecasting software is provided as a supplement (any groups of countries).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNoneClinical Protocols https://arxiv.org/abs/2004.06021 Funding StatementFunding: partially supported by NSF grant DMS-1901796 and the Simons Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExtended data and a complete theory are in arxiv 2004.06021v5 (q-bio); the programs forecasting the total number of detected infections for phase 2 are attached. https://arxiv.org/abs/2004.06021